Hybrid Molecules for Neurodegenerative Diseases
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: closed (30 March 2024)
Special Issue Editor
Interests: synthesis and biological studies on anti-inflammatory and antioxidant agents, on inhibitors of enzymes implicated in the inflammation and in the coagulation process in general; correlation of inflammation with cancer; neurodegeneration; antioxidant activity; theoretical and experimental calculation of physicochemical parameters implicated in biological response; use of computational chemistry in drug design as well as bioactive compounds of natural origin, e.g., essential oils
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hybrid drugs, described as “single-molecule multiple targets” or “multiple ligands”, are often considered the most sophisticated form of combination therapy. Hybrid drug design involves combining various compounds or pharmacophores in order to generate new bioactive molecules. This concept strategy has been extensively employed in order to target various human diseases and enhance the effects of bioactive compounds; this enables pleiotropic results to be achieved and small molecules to be made visible in order to overcome drug resistance. Compared to therapy that involves drug combination/cocktail drugs, hybrid molecules do not present drug–drug interactions. Thus, they have the advantage of “one plus one is much potent than two”. However, the druglikeness of the hybrid molecules remains a challenge.
Neurodegenerative diseases include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, and prion diseases. The multifactorious etiology of neurodegenerative diseases highlights the necessity of hybrid drugs. Designing hybrid-multitarget therapeutic compounds is a prospective approach to developing an effective treatment for neurodegenerative diseases.
Numerous issues must be considered and additional research should be performed in order to develop novel hybrid compounds for therapeutic use that continue to consider other off-target adverse effects.
Prof. Dr. Dimitra Hadjipavlou-Litina
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegenaration
- hybrid drugs
- pharmacophore
- multitarget
- druglikeness
